- Details
- The management of stage 2A seminoma has been consistent over the past several years, consisting of either radiotherapy or primary chemotherapy. Cure rates with these approaches are excellent but are also associated with many life years of potential cumulative toxicities. At the 2021 GU ASCO meeting, Dr. Siamak Daneshmand presented a phase 2 study in stage two seminoma, the Surgery In Early Metasta...
|
- Details
- Andrea Necchi, MD, and Philippe Spiess, MD, MS, FRCS(C), FACS, join Alicia Morgans, MD, MPH, to discuss the new international effort to develop a Global Society of Rare Genitourinary (GU) Cancers. The Global Society of Rare Genitourinary Tumors (GSRGT) will have both an educational and research mission to promote evidence-based diagnostic and treatment standards across the world through conference...
|
- Details
- Philippe Spiess, MD, MS, FRCS(C), FACS, and Jad Chahoud, MD, MPH present expert insight on the management of penile cancers in a conversation with Ashish Kamat, MD, MBBS. Dr. Spiess focuses the discussion on treatment options for advanced penile cancer but starts by laying out updates to the staging of the disease. He also describes how human papillomavirus (HPV) positive or negative cancers have...
|
- Details
- Mike Craycraft, Testicular Cancer Survivor, Clinical Pharmacist and Founder of the Testicular Cancer Society joins Alicia Morgans in this special Testicular Cancer Awareness podcast. Mike shares what drove him to launch the Testicular Cancer Society, a nonprofit raising awareness for testicular cancer, promoting self-examination and helping survivors and caregivers navigate the diagnosis and treat...
|
- Details
- Darren Feldman joins Alicia Morgans to discuss clinical trials and the treatment of testicular cancer. Dr. Feldman provides an overview of the TIGER trial, an international randomized, multicenter open-label phase III trial. The study is an international collaboration with European sites. Collaborators on the study include the National Cancer Institute, the European Organization for Research and T...
|
- Details
- Alicia Morgans and Brad McGregor discuss rare genitourinary histologies and the efforts to find treatment options for populations not always included in clinical trials. Most clinical trials are developed and designed for the most common subtypes, not including atypical variant histologies often found in bladder and prostate cancers. Given the tumor agnostic approach of immunotherapy, Brad and his...
|
